We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A discontinued heart disease drug may find new life as a treatment for sickle cell disease, with Roche handing off development of its antibody inclacumab to Global Blood Therapeutics.